Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract

Leukemia. 2020 May;34(5):1467-1471. doi: 10.1038/s41375-019-0678-3. Epub 2019 Dec 13.

Guangzhen Hu¹, Jessica L Phillips¹, Surendra Dasari², Hailey K Jacobs¹, Rebecca A Luchtel¹, Naoki Oishi^{1

3}, Tanya Hundal¹, Nada H Ahmed^{1

4}, Akira Satou^{1

5}, Alan L Epstein⁶, N Nora Bennani⁷, Grzegorz S Nowakowski^{7

8}, Joseph A Murray⁹, Andrew L Feldman¹⁰

¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
² Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
³ Department of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
⁴ Department of Clinical Pathology, Suez Canal University, Ismailia, Egypt.
⁵ Department of Surgical Pathology, Aichi Medical University Hospital, Aichi, Japan.
⁶ Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.
⁷ Division of Hematology, Mayo Clinic, Rochester, MN, USA.
⁸ Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA.
⁹ Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
¹⁰ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. feldman.andrew@mayo.edu.

No abstract available

Publication types